Drug intelligence / Profile preview

vurolenatide

Development stage: Phase 2
Lead developer: Innovate Biopharmaceuticals
Modality: Peptides
Administration: Subcutaneous

Overview

Vurolenatide (PB1023) is a long-acting analog of the human peptide oxyntomodulin, developed as a therapeutic agent for metabolic diseases. It acts as an agonist at both the glucagon-like peptide 1 receptor and the glucagon receptor. The drug is being investigated primarily for the treatment of obesity and type 2 diabetes mellitus. By activating these receptors, vurolenatide aims to reduce appetite, promote weight loss, and improve glycemic control. The developer of vurolenatide is Phenomix Sciences.

Other names: XTEN GLP-1

Targets

GCGR (Glucagon receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on vurolenatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vurolenatide.

Explore the full profile